PNC Financial Services Group Inc. Boosts Stake in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

PNC Financial Services Group Inc. lifted its holdings in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 2,319.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 26,078 shares of the biopharmaceutical company’s stock after buying an additional 25,000 shares during the period. PNC Financial Services Group Inc.’s holdings in Sangamo Therapeutics were worth $27,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. Charles Schwab Investment Management Inc. lifted its stake in Sangamo Therapeutics by 5.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,103,326 shares of the biopharmaceutical company’s stock valued at $956,000 after acquiring an additional 57,125 shares during the period. FMR LLC lifted its position in Sangamo Therapeutics by 16.5% during the third quarter. FMR LLC now owns 544,003 shares of the biopharmaceutical company’s stock valued at $471,000 after purchasing an additional 77,032 shares during the period. State Street Corp boosted its holdings in Sangamo Therapeutics by 28.0% in the third quarter. State Street Corp now owns 664,621 shares of the biopharmaceutical company’s stock worth $576,000 after purchasing an additional 145,400 shares during the last quarter. XTX Topco Ltd grew its position in Sangamo Therapeutics by 167.8% in the 3rd quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company’s stock worth $90,000 after purchasing an additional 64,981 shares during the period. Finally, Geode Capital Management LLC grew its position in Sangamo Therapeutics by 14.6% in the 3rd quarter. Geode Capital Management LLC now owns 2,138,309 shares of the biopharmaceutical company’s stock worth $1,853,000 after purchasing an additional 272,123 shares during the period. 56.93% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on SGMO shares. StockNews.com downgraded Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, December 24th. Jefferies Financial Group cut their price target on Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating for the company in a research note on Tuesday, December 31st. Royal Bank of Canada reiterated a “sector perform” rating and issued a $2.00 price objective on shares of Sangamo Therapeutics in a research note on Tuesday, March 18th. Wells Fargo & Company cut their target price on shares of Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating for the company in a research report on Tuesday, December 31st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Sangamo Therapeutics in a report on Monday, January 27th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, Sangamo Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $5.17.

Sangamo Therapeutics Trading Up 1.5 %

Sangamo Therapeutics stock opened at $0.86 on Friday. Sangamo Therapeutics, Inc. has a 12-month low of $0.30 and a 12-month high of $3.18. The firm has a market capitalization of $192.64 million, a price-to-earnings ratio of -1.14 and a beta of 1.49. The firm has a 50 day moving average of $1.05 and a 200 day moving average of $1.40.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings data on Monday, March 17th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. The firm had revenue of $7.55 million during the quarter, compared to analysts’ expectations of $11.70 million. On average, analysts predict that Sangamo Therapeutics, Inc. will post -0.46 EPS for the current year.

Sangamo Therapeutics Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.